RM-11, an isoxazole derivative, accelerates restoration of the immune function in mice treated with cyclophosphamide

Pharmacological Reports

Volumn 60, Issue 2, 2008, Pages 183-189

  Zimecki, Michał ^a   Artym, Jolanta ^a   Ryng, Stanisław ^b   Obmińska Mrukowicz, Bozena ^c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c WROCLAW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

Author keywords

Cyclophosphamide; Immune response; Isoxazoles; Methotrexate; Mice

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOLOGIC AGENT; ISOXAZOLE DERIVATIVE; METHOTREXATE; OVALBUMIN; RM 11;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCING CELL; ARTICLE; CD19+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE PERCENTAGE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOFLUOROMETRY; DELAYED HYPERSENSITIVITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOMODULATION; IN VITRO STUDY; MALE; MOUSE; MYELOPOIESIS; NONHUMAN; PHENOTYPE; SHEEP ERYTHROCYTE; T LYMPHOCYTE;

EID: 49749096075     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Artym J, Zimecki M, Kruzel ML: Effect of lactoferrin on the methotrexate-induced suppression of the cellular and humoral immune response in mice. Anticancer Res, 2004, 24, 3831-3836.
2. Artym J, Zimecki M, Kruzel ML: Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin. Int Immunopharm, 2004, 4, 1149-1157.
3. Artym J, Zimecki M, Kruzel ML: Reconstitution of the cellular immune response by lactoferrin in cyclo-phosphamide-treated mice is correlated with renewal of T-cell compartment. Immunobiology, 2003, 207, 197-205.
4. Artym J, Zimecki M, Paprocka M, Kruzel ML: Orally administered lactoferrin restores humoral immune response in immunocompromised mice. Immunol Lett, 2003, 89, 8-15.
5. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated T cells. J Clin Invest, 1998, 102, 322-328.
6. Hemendinger RA, Bloom SE: Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo. Immunopharmacology, 1996, 35, 71-82.
7. Johnkoski JA, Peterson SM, Doerr RJ, Cohen SA: Levamisole regulates the proliferation of murine liver T cells through Kupffer-cell-derived cytokines. Cancer Immunol Immunother, 1996, 43, 299-306.
8. Kimball ES, Fisher MC: Absence of significant effects by levamisole on circulating neutrophil levels in normal mice treated with 5-FU. Immunopharmacology, 1994, 27, 137-143.
9. Lagrange PH, Mackaness GB, Miller TE, Pardon P: Influence of dose and route of antigen injection on the immunological function of T cells. J Exp Med, 1974, 139, 528-542.
10. Maczyński M, Zimecki M, Drozd-Szczygieł E, Ryng S: The synthesis, pbysicochemical properties and immunological activity of 5-amino-3-methylisoxazolo[5,4-d] 4-pyrimidinone derivatives. Cell Mol Biol Lett, 2005, 10, 613-623.
11. Mishell RI, Dutton RW: Immunization of dissociated spleen cell cultures from normal mice. J Exp Med., 1967, 126, 423-442.
12. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G: Immune and inflammatory response in TNF α-deficient mice: a critical requirement for TNFα in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med, 1996, 184, 1397-1411.
13. Rollinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H: Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med, 1977, 145, 455-459.
14. Ryng S, Machon Z, Wieczorek Z, Zimecki M, Mokrosz M: Synthesis, immunomodulating effects and structure activity relationship of new N-phenyl-5-amino-3-methyl-isoxazole-4-carboxamides. Eur J Med Chem, 1998, 33, 831-836.
15. Ryng S, Machoń Z, Wieczorek Z, Zimecki M: Synthesis and immunological activity of new 5-amino-3-methyl 4-amido and 4-ureilene isoxazole derivatives. Pharmazie, 1999, 54, 359-361.
16. Ryng S, Sonnenberg Z, Zimecki M: RM11, a new isoxazole derivative, is a potent stimulator of the humoral and cellular immune response in mice. Arch Immunol Ther Exp, 2000, 48, 127-131.
17. Ryng S, Zimecki M, Maczyński M, Chodaczek G, Kocieba M: Immunosuppresive activity of an isoxazolo [5,4-e] triazepine - compound RM33. I. Effects on the humoral and cellular immune response in mice. Pharmacol Rep, 2005, 57, 195-202.
18. Ryng S, Zimecki M, Sonnenberg Z, Mokrosz MJ: Immunomodulating action and structure-activity reiationship of substituted phenylamides of 5-amino-3-methylisoxazole-4-carboxylic acid. Arch Pharm (Weinheim), 1999, 332, 158-162.
19. Ryng S, Zimecki M: Search for new lead structures in the isoxazole heterocyclic system. Acta Pol Pharm, 2003, 60, 225-228.
20. Samira S, Ferrand C, Peled. A, Nagler A, Tovbin Y, Ben-Hur H, Taylor N et al.: Tumor necrosis factor promotes human T-cell development in nonobese diabetic/severe combined immunodeficient mice. Stem Cells, 2004, 22, 1085-1100.
21. Wolf ML, Weng WK, Stieglbauer KT, Shah N, Le Bien TW: Functional effect of IL-7-enhanced CD19 expression on human B-cell precursors. J Immunol, 1993, 151, 138-148.
22. Zielinski CC, Stuller I, Dorner F, Potzi P, Muller C, Eibl MM: Impaired primary, but not secondary, immune response in breast cancer patients under adjuvant chemotherapy. Cancer, 1986, 58, 1648-1552.
23. Zimecki M, Ryng S, Maczyński M, Chodaczek G, Kocieba M, Kuryszko J, Kaleta K: Immunosuppressory activity of an isoxazolo [5,4-e] triazepine - compound RM33 II. Effects on the carrageenan-induced inflammation. Pharmacol Rep, 2006, 58, 236-241.
24. Zuniga-Pfluckcr JC, Di J, Leonardo MJ: Requirement for TNF-α and IL-1α in fetal thymocyte commitment and differentiation. Science, 1991, 268, 1906-1909.